Evidence map›Paper›PMID 37854319›Full record

ReviewOpen life sciences2023

IL-17 in osteoarthritis: A narrative review.

Juan Xiao, Ping Zhang, Fang-Lan Cai, Cheng-Gen Luo, Tao Pu, Xiao-Li Pan, Mei Tian

Open access · goldAbstract readReview
In one paragraph

Review in Open life sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Integrative multi-omics identifiesFrontiers in immunology · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Juan XiaoDepartment of Rheumatology and Immunology Department, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Ping ZhangThe First School of Clinical Medicine, Zunyi Medical University, Zunyi 563000, China.
Fang-Lan CaiDepartment of Rheumatology and Immunology Department, Zunyi Medical University, Zunyi 563000, China.
Cheng-Gen LuoThe First School of Clinical Medicine, Zunyi Medical University, Zunyi 563000, China.
Tao PuDepartment of Nephrology and Rheumatology, Moutai Hospital, Renhuai 564500 Guizhou, China.
Xiao-Li PanDepartment of Rheumatology and Immunology Department, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Mei TianDepartment of Rheumatology and Immunology Department, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Zunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a painful joint disease that is common among the middle-aged and elderly populations, with an increasing prevalence. Therapeutic options for OA are limited, and the pathogenic mechanism of OA remains unclear. The roles of cytokines and signaling pathways in the development of OA is a current research hot spot. Interleukin (IL)-17 is a pleiotropic inflammatory cytokine produced mainly by T helper 17 cells that has established roles in host defense, tissue repair, lymphoid tissue metabolism, tumor progression, and pathological processes of immune diseases, and studies in recent years have identified an important role for IL-17 in the progression of OA. This narrative review focuses on the mechanisms by which IL-17 contributes to articular cartilage degeneration and synovial inflammation in OA and discusses how IL-17 and the IL-17 signaling pathway affect the pathological process of OA. Additionally, therapeutic targets that have been proposed in recent years based on IL-17 and its pathway in OA are summarized as well as recent advances in the study of IL-17 pathway inhibitors and the potential challenges of their use for OA treatment.

Indexed as

interleukin-17joint cartilageosteoarthritissynoviumtarget

Identifiers

PMID37854319
PMCPMC10579884
OpenAlexW4387645719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.